Shares of biopharmaceutical company MorphoSys dipped after it successfully raised €102.7 million ($111.7 million) in a capital increase. The funds will be used to fast-track the launch of a myelofibrosis drug and support the clinical development of important pipeline programs.

At 1145 GMT on Thursday, MorphoSys shares experienced a 5% decline, currently priced at EUR33.21. However, the stock is still up 34% since last week following the release of positive clinical-trial data for their investigational drug, pelabresib, on Monday.

As part of the capital increase, MorphoSys issued 3.4 million new shares at a price of EUR30 each, which represents a 14% discount compared to Wednesday's closing price of EUR34.96.

A late-stage clinical trial demonstrated that pelabresib, when combined with ruxolitinib, provided significant benefits compared to the placebo and ruxolitinib alone for patients with myelofibrosis, a form of bone marrow cancer. Ruxolitinib is currently the standard of care for this condition.

In addition to preparing for the launch of pelabresib as a first-line treatment for myelofibrosis, MorphoSys aims to advance their key pipeline programs towards regulatory approval and strengthen their financial position.

Asia-Pacific Stocks Mostly Climb

Intel Unveils New PC Chips for Artificial Intelligence Tasks

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Apple Unveils Newest iPhones
News

Apple Unveils Newest iPhones

Apple Inc. recently announced its latest lineup of iPhones with improved features, enhanced design, and USB-C charging....

Shifting Momentum in U.S. Stocks
News

Shifting Momentum in U.S. Stocks

Expert Jonathan Krinsky warns of potential downside risks in U.S. stocks as momentum slows, with small-cap stocks emergi...

Harmony Gold Mining Financial Results
News

Harmony Gold Mining Financial Results

Harmony Gold Mining reports strong financial results with significant profit increase, higher gold production, and robus...

Record Low Contract Signings for Previously Owned Homes in October
News

Record Low Contract Signings for Previously Owned Homes in October

Contract signings for previously owned homes reached a record low in October due to limited supply and high housing cost...